Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
(NasdaqGM:LGND),(NYSE MKT:PTHS), Pelthos plans to launch ZELSUVMI(TM) for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under […]